Guselkumab treatment of psoriasis results in sustained reduction of systemic inflammatory biomarkers to week 48 in three phase III randomized controlled trials
{{output}}
Increased risk of major adverse cardiac events (MACE) may be linked to systemic inflammation for patients with psoriasis. Guselkumab is an effective treatment for psoriasis and psoriatic arthritis that was previously shown to reduce inflammatory biomarkers in ... ...
